Universidad del Norte, Barranquilla Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT01984411
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Universidad del Norte | Universidad del Norte, Barranquilla, Colombia

Active Ingredients

Drugs in Phase 4 Trials (4)

ertapenem (invanz) (1 trial)

meropenem (merrem) (1 trial)

piperacillin (pipracil) (1 trial)

tazobactam (Zosyn) (1 trial)

Drugs in Phase 3 Trials (1)

iohexol (Omnipaque) (1 trial)

Drugs in Other Trials (1)

sildenafil (viagra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Coronary Artery Disease (Phase 3)

Enterobacteriaceae Infections (Phase 4)

Escherichia coli Infections (Phase 4)

Heart Diseases (Phase 3)

Infections (Phase 4)

Klebsiella Infections (Phase 4)

Myocardial Ischemia (Phase 3)

Pneumonia (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 6